
Recursion Pharmaceuticals (PRNewsfoto/Recursion Pharmaceuticals)
Recursion, the Salt Lake City company that uses AI to find and develop drugs, said Nov. 18 it had reached agreement with the FDA on the design of a registrational Phase 3 trial of REC-4881, an investigational oral MEK1/2 inhibitor for adults with familial adenomatous polyposis (FAP) who have had a colectomy or proctocolectomy. The trial’s primary endpoint, event-free survival, will count removal of an adenoma 10 mm or larger in either the upper or lower GI tract as an event. Recursion plans to start the trial in the second half of 2027.
Without surgery to remove the colon, the lifetime risk of colorectal cancer in people with classic FAP approaches 100%. FAP is caused by mutations in the APC gene. After colectomy, polyps can still form in the remaining rectum or ileal pouch and in the upper gastrointestinal (GI) tract in FAP. Patients face lifelong endoscopic surveillance, repeated polyp removal and, in some cases, further major surgery. FAP currently has no FDA-approved drug therapy.
The Recursion trial will measure time from randomization to the first qualifying event. Other events include meeting prespecified criteria for FAP-related surgery, developing high-grade dysplasia or cancer and death. “Adenomas 10 millimeters and larger are associated with increased cancer risk and are nowadays routinely removed in patients with FAP. However, removal carries risks of bleeding and perforation, alongside the burden of repeated procedures and intensive surveillance,” Evelien Dekker, a professor of gastrointestinal oncology at Amsterdam University Medical Center, said in the release.
Recursion expects to enroll about 200 adults in the randomized, double-blind, placebo-controlled trial, which will include a prespecified interim analysis. The trial will test a 4 mg dose, with the dosing schedule to be set using data from the ongoing TUPELO trial. Key secondary endpoints include progression on the modified Spigelman scale, which grades the severity of duodenal polyposis, and total polyp burden.
The design builds on the ongoing Phase 1b/2 TUPELO trial, whose earlier results Drug Discovery & Development covered in December 2025. In data presented Nov. 2, total polyp burden fell by a median of 47% among 15 patients after 12 weeks of REC-4881 at 4 mg once daily. Twelve weeks after treatment stopped, 11 of 13 evaluable patients (85%) still had a lower polyp burden than at baseline. Of 26 patients evaluated for safety, four (15%) had a grade 3 treatment-related adverse event. There were no grade 4 or 5 treatment-related events.
Six of eight patients who had polyps larger than 5 mm at baseline had fewer polyps in that size category after 12 weeks. TUPELO grouped all polyps larger than 5 mm together, so the results leave open how many adenomas met the Phase 3 size threshold of 10 mm or larger.
Takeda first developed REC-4881 as TAK-733, and Recursion licensed it in 2020. Recursion says it used phenotypic screening with its AI models to identify the drug’s potential in FAP. After narrowing TUPELO enrollment to patients 55 and older while it evaluated adverse events, Recursion reopened enrollment to adults 18 and older, R&D World reported in July.
Biodexa Pharmaceuticals is already running a registrational Phase 3 trial of eRapa, an oral formulation of rapamycin, in patients with FAP. The company reported Nov. 9 that it had enrolled 112 of a planned 168 participants.
Filed Under: clinical trials, Gastroenterology, machine learning and AI, Rare disease, Regulatory affairs



